arrow
A

Alfonso Cortés

university hospital ramon y cajal
H指数:17
被引数:2,144

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study☆

一种基于曲妥珠单抗–帕妥珠单抗和T-DM1的病理反应适应策略在HER2阳性早期乳腺癌中的应用:PHERGain-2研究☆

2026-05-060
OA
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
2025-06-040
OAAI
Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study
BREAST
IF7.9
2024-12-010
OAAI
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study
CANCER
IF5.1
2024-05-166
OAAI
Efficacy and safety of first-line atezolizumab plus bevacizumab plus paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
2024-05-020
PRE
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
LANCET
IF88.5
2024-04-0116
PRE
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study
2022-12-036
OAAI
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments
2022-05-0114
OAAI
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

奥拉帕尼联合聚乙二醇化脂质体阿霉素治疗铂耐药卵巢癌,无论BRCA状态如何: GEICO II期试验 (ROLANDO研究)

2021-08-0119
OAAI